Videos

Here are the top 5 biosimilar articles for the week of January 3, 2022.

Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute, explains pricing issues for reference drugs and biosimilars.

The Center for Biosimilars® spoke recently with Chad Landmon, chair of the Intellectual Property and Food and Drug Administration Practice Groups at Axinn, a New York–based antitrust, intellectual property, and litigation law firm.

Wayne Winegarden, PhD, discusses his savings analysis for adalimumab and etanercept biosimilars and their potential market share.

An economist weighs in on whether interchangeable status will help adalimumab biosimilars succeed.

Here are the top 5 biosimilar articles for the week of December 13, 2021.

Etanercept and adalimumab biosimilar competition is not only necessary to drive down prices, it’s long overdue, according to Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute.

Here are the top 5 biosimilar articles for the week of December 6, 2021.

Here are the top 5 biosimilar articles for the week of November 29, 2021.

Karen van Caulil, PhD, president and CEO at Florida Alliance for Healthcare Value, discusses the difficulty her institution has had in getting providers and employers to switch to biosimilars.

Here are the top 5 biosimilar articles for the week of November 22, 2021.

The utilization rates for biosimilars in community oncology have been much higher than for other disease categories and are only expected to rise, says Steven Yates, MD.

Here are the top 5 biosimilar articles for the week of November 15, 2021.

The World Health Organization (WHO) has issued a fresh draft of its biosimilar evaluation guidelines. Medicines for Europe science and policy expert Marta Baldrighi, PhD, explains the significance.

Steven Yates, MD, explains how the relationships that nurses have with patients can influence biosimilar acceptance.

Here are the top 5 biosimilar articles for the week of November 8, 2021.

A consultant who specializes in helping Chinese biosimilar companies market their products in the European Union discusses the challenges and opportunities.

Steven Yates, MD, discusses Intermountain Healthcare's policies surrounding switching patients from reference products to biosimilars.

Here are the top 5 biosimilar articles for the week of November 1, 2021.

Ali Ahmed, senior vice president of biosimilars for Fresenius Kabi USA discusses FDA review of the company’s Stimufend pegfilgrastim biosimilar candidate and the marketing of this product.

Two AmerisourceBergen/Xcenda policy experts discuss the coming wave of pharmacy benefit biosimilars, formulary decisions, pricing transparency, and the Biden Administration’s push for lower-cost biologics.

Here are the top 5 biosimilar articles for the week of October 25, 2021.

Reimbursement concerns and the uncertainty of how interchangeability will impact biosimilar adoption are hot-button issues in the biosimilar space, Cate Lockhart, PharmD, PhD, MS, explains in this interview.

Here are the top 5 biosimilar articles for the week of October 18, 2021.

In this interview with The Center for Biosimilars®, Amgen biosimilars expert Jen Norton discusses regulatory and policy incentives, interchangeable biosimilars, and market share gains.

Here are the top 5 biosimilar articles for the week of October 11, 2021.

The Center for Biosimilars® speaks with Polpharma Biologics executives Alex Moulson, vice president of Development, and Pawel Lewinski, head of Portfolio and Commercial Strategy, about the company's biosimilar pipeline.

Here are the top 5 biosimilar articles for the week of October 4, 2021.

Here are the top 5 biosimilar articles for the week of September 27, 2021.

Adrian van den Hoven, director general for Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, analyze findings from the group's recent survey of European biosimilar markets.